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LUNG REDUCTION SURGERY: A TRUE ADVANCE? 
Valerie W. Rusch, MD, New York, N.Y. 
A surgical approach to the treatment of patients with 
diffuse pulmonary emphysema was first reported 
by Brantigan, Mueller, and Kress a during the 1950s. 
They proposed that "reduction in lung volume by 
resection of the most useless and functionless areas of 
lung tissue" would improve lung function by partially 
restoring the "elasticity" of the lung and chest wall. a By 
1959, Brantigan had performed lung reduction via 
sequential bilateral thoracotomies in 33 patients. Six 
patients (18%) died after the first operation, none died 
after the second operation, and all surviving patients 
were in improved condition symptomatically or objec- 
tively. 1 Brantigan's high operative mortality discour- 
aged surgeons from operating on patients with diffuse 
emphysema until Cooper and his associates in St. 
Louis decided to explore lung reduction as an alterna- 
tive to transplantation. Their initial report of bilateral 
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pneumectomy via median sternotomy in 20 patients 
with no postoperative deaths and a definite early 
improvement in pulmonary function immediately 
stimulated other surgeons to explore the use of this 
surgical technique. 2 
In this issue of the JOURNAL, three groups report 
their experience with lung reduction surgery. Gais- 
sert and coworkers, 3 from St. Louis, update their 
results with bilateral pneumectomy and assess its 
role as an alternative or bridge to transplantation. 
Keenan and colleagues, 4 at the University of Pitts- 
burgh, report their early experience with unilateral 
thoracoscopic lung reduction, primarily using a stapled 
technique. McKenna and associates, s prompted by 
Wakabayashi's controversial experience with thoraco- 
scopic laser bullectomy, 6 report he preliminary results 
of a randomized prospective trial comparing Wakaba- 
yashi's technique to unilateral thoracoscopic lung re- 
duction with staples. Taken as a whole, these reports 
suggest that lung reduction surgery can now be per- 
formed with acceptable morbidity and mortality and 
may benefit a subset of patients with disabling chronic 
obstructive pulmonary disease. However, they raise as 
many questions as they answer, and they demand a 
sober evaluation of this innovative surgical treatment. 
Unanswered questions include the surgical selectiofl 
criteria, the role of preoperative exercise conditioning, 
the degree to which lung reduction improves on exer- 
cise conditioning, the optimal surgical technique, the 
tests necessary to measure outcome, and the cost 
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effectiveness of lung reduction surgery compared with 
continued medical management. 
With respect to selection criteria, the members of 
the Washington University group believe they can 
identify the ideal candidate by the presence of 
severe thoracic hyperinflation, flattened iaphragm 
and immobile chest wall, and heterogeneous regions 
of disease on computed tomographic and ventila- 
tion/perfusion scans. They do not think that selec- 
tion of the larger group of patients with less than 
ideal criteria is clear and are not yet able to define 
specific exclusion criteria. However, the Pittsburgh 
group found that the combination of hypercarbia 
and reduced diffusion of carbon monoxide in the 
lung identified patients with a serious postoperative 
risk. Currently, the preoperative valuation of pa- 
tients may include complete pulmonary function 
testing, exercise testing, computed tomographic and 
ventilation/perfusion lu g scanning (sometimes with 
single photon emission computed tomographic im- 
aging), dyspnea index measurement, and nutritional 
assessment, along with investigation f comorbid 
medical conditions as individually indicated. With 
thousands of dollars being spent to assess urgical 
eligibility, it will be important o define which tests 
are absolutely necessary because they clearly predict 
operative risk and outcome. 
The Washington University group believes that a 
supervised pulmonary rehabilitation program is an 
integral part of perioperative care for lung reduction 
surgery, just as it has been for lung transplantation. 
In contrast, the Pittsburgh group encourages but 
does not require participation in a rehabilitation 
program, and McKenna and coworkers 5 used reha- 
bilitation only in the postoperative period. Yet the 
hospital stay and morbidity are similar in all three 
studies. Does this similarity indicate that patients 
tolerate the smaller video-assisted thoracic surgery 
(VATS) incisions without preoperative condition- 
ing, or does it reflect differences in patient selec- 
tion? Can some patients undergo lung reduction 
surgery without a rehabilitation program? Do some 
patients benefit so much from rehabilitation that lung 
reduction can be deferred? A prospective trial ran- 
domizing patients to undergo r not undergo pulmo- 
nary rehabilitation or a trial withholding surgery until 
patients have reached a plateau in the rehabilitation 
program could answer these questions. 
Many questions remain unanswered regarding 
surgical technique. The merits and disadvantages of 
median sternotomy for simultaneous bilateral 
pneumectomy versus those of VATS lung reduction 
(unilateral or sequential bilateral) are undefined. 
Can the areas of lung to be removed be defined as 
well thoracoscopically asat median sternotomy? Is
the morbidity of VATS less? Is bovine pericardium 
reinforcement of staple lines, an expensive method, 
always necessary, or is endoscopic stapling in con- 
junction with pleurodesis just as effective? On the 
basis of limited data, many surgeons consider laser 
bullectomy unsafe. McKenna's results now confirm 
a higher rate of delayed pneumothorax after laser 
ablation and also show that it is less effective than 
stapling. His trial is the first to compare surgical 
techniques directly. More such trials are needed. 
After patients leave the hospital, how much care 
and rehabilitation do they need? How many tests 
are required to assess outcome, and how frequently 
need they be performed? How does the cost of lung 
reduction surgery compare with that of continued 
medical management? McKenna's original abstract 
presented at the American Association for Thoracic 
Surgery meeting noted that hospital charges for 
VATS lung reduction were approximately $50,000. 
This cost does not include preoperative assessment, 
rehabilitation, and follow-up tests. Are the high 
immediate costs offset by the advantages--patients 
no longer requiring oxygen, decreasing their medi- 
cations and hospitalizations for disease exacerba- 
tions, and being able to return to work? Are the 
promising initial results of lung reduction surgery 
sustained over the long term or do some patients 
experience inexorable disease progression? 
With an estimated prevalence of 2 million cases of 
emphysema in the United States, the potential medi- 
cal, social, and economic impact of lung reduction 
surgery is enormous. Evaluation of this new treatment 
through carefully designed prospective clinical trials is 
urgently needed. It is important that these trials ask 
focused questions in large nough numbers of patients 
observed for long enough periods (a minimum fol- 
low-up of 2 to 5 years) to yield definitive answers. 
Measurements of economic osts should be incorpo- 
rated into these trials. In an era of shrinking health 
care dollars, premature reporting of the results of lung 
reduction surgery in small numbers of patients will 
only perpetuate the frequent perception of surgeons 
as specialists who strive to perform expensive and risky 
operations. In an era of shrinking resources for clinical 
research, institutions interested in lung reduction shr- 
gery might consider pooling their efforts to identify 
important questions, maximize patient accrual, and 
prevent repetitive or overlapping trials. In an era when 
many important research questions can be answered 
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only through complex basic science techniques or 
collaboration with other specialties, thoracic surgeons 
have an unusual opportunity to define the true benefit 
of a treatment hat could affect the well-being of 
thousands of patients each year. We as thoracic sur- 
geons should exploit that opportunity. 
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